VOLITIONRX LIMITED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.77 USD | 0.00% |
|
-13.39% | +6.00% |
| 14/05 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
| 13/05 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 44.59L 37Cr | Sales 2025 * | 1.62Cr 134.86Cr | Capitalization | 6.38Cr 530.94Cr |
|---|---|---|---|---|---|
| Net income 2024 * | -3.5Cr -291.38Cr | Net income 2025 * | -3.1Cr -258.08Cr | EV / Sales 2024 * | 11.8 x |
| Net cash position 2024 * | 1.12Cr 93Cr | Net Debt 2025 * | 1.39Cr 115.72Cr | EV / Sales 2025 * | 4.8 x |
| P/E ratio 2024 * |
-1.71
x | P/E ratio 2025 * |
-2.41
x | Employees | 110 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.32% |
More Fundamentals
* Assessed data
More news
Latest transcript on VolitionRx Limited
More recommendations
| 1 week | -13.39% | ||
| Current month | -15.55% | ||
| 1 month | +26.67% | ||
| 3 months | -27.62% | ||
| 6 months | +4.04% | ||
| Current year | +6.00% |
1 week
0.74
0.87
1 month
0.591.02
Current year
0.571.23
1 year
0.551.79
3 years
0.554.14
5 years
0.556.84
10 years
0.559.28
| Managers | Title | Age | Since |
|---|---|---|---|
Cameron Reynolds
CEO | Chief Executive Officer | 53 | 06/11/06 |
Terig Hughes
DFI | Director of Finance/CFO | 54 | 01/21/01 |
Gaetan Michel
COO | Chief Operating Officer | 51 | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cameron Reynolds
CEO | Chief Executive Officer | 53 | 06/11/06 |
Martin Faulkes
CHM | Chairman | 80 | 06/11/06 |
Guy Innes
BRD | Director/Board Member | 67 | 06/11/06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/24/20 | 0.7549 | -1.96% | 21 389 |
| 17/24/17 | 0.77 | -3.75% | 75,235 |
| 16/24/16 | 0.8 | +1.66% | 50,923 |
| 15/24/15 | 0.7869 | +4.92% | 99,280 |
| 14/24/14 | 0.75 | -14.53% | 312,875 |
Delayed Quote Nyse, May 20, 2024 at 08:58 pm IST
More quotes
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.77
USD
Average target price
3.725
USD
Spread / Average Target
+383.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.00% | 6.38Cr | |
| -30.62% | 929.66Cr | |
| -8.13% | 310.33Cr | |
| +26.81% | 286.55Cr | |
| -14.31% | 216.99Cr | |
| -17.96% | 174.91Cr | |
| +66.34% | 150.36Cr | |
| +30.08% | 81Cr | |
| -1.97% | 76Cr | |
| -28.47% | 53Cr |
- Stock Market
- Equities
- VNRX Stock
